-
FDA Advisory Committee Votes on Investigational Medicine MetreleptinAstraZeneca and Bristol-Myers Squibb Companyhave announced that FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment2013/12/13
-
CVS Caremark and Cardinal Health Announce Creation of Largest Generic Sourcing Entity in USCVS Caremark and Cardinal Healthhave signedan agreement to form the largest generic sourcing entity in the US, which is the world's largest generic drug market. Both companies are contributing their s2013/12/12
-
£3 Million Dementia Consortium Launched to Boost Dementia Drug DiscoveryAs the UK today hosts the first G8 summit on dementia research, a new £3 million Dementia Consortium bringing together research experts from the charitable, academic and private sectors has laun2013/12/12
-
Anakinra licensed in UK to treat CAPS in infants and adultsThe Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has granted a licence to an interleukin-1 (IL-1) inhibitor Anakinra (Kineret) for the treatment of cryopyrin-associated periodi2013/12/11
-
BMS Presents 4-Year Data from Phase III DASISION TrialBristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.have announced 4-year follow-up data from the PhaseIII DASISION study of Sprycel (dasatinib) 100 mg once daily versus imatinib (4002013/12/11
-
China Finally Allows FDA To Add InspectorsPharmalot's Ed Silverman reported that after a year of frustration and delay, the White House has finally reached agreement with the Chinese government to allow FDA to boost its inspection team as par2013/12/10
-
AstraZeneca's influenza vaccine Fluenz Tetra gets European approvalAstraZeneca has received marketing authorisation from the European Commission (EC) for its new four-in-one influenza vaccine Fluenz Tetra for the prevention of influenza in children and adolescents fr2013/12/10
-
Hovione: New Inhalation Capsule Filling Machine Fills Market GapHovione has announced the expansion of its inhalation drug product development services with the introduction of a high precision MG2 FlexaLAB capsule filling machine. This investment is in respons2013/12/9
-
AstraZenec​a Announces Initiation of Two Additional Global Studies for BRILINTA (Ticagrelo​r)AstraZeneca has announced plans toconduct two new Phase IIIb clinical studies as part of PARTHENON, the company's largest clinical trial programme involving over 80,000patients, with Canada actively p2013/12/9
-
Risk Assessment for Ascertaining GMP for ExcipientsThe EU has published the comments received from the industry regarding the publication of the draft guidelines on the formalised risk assessment for ascertaining the appropriate good manufacturing pra2013/12/6